Study Graphic

You may be eligible if:

  • You are a healthy male or female 18-55 years of age.
  • You are able to meet all eligibility criteria.
  • You are able to comply with all study visits.

Study Number: B7981017

Be compensated for your time: You will receive up to $4650.00 for completion of the study.

The Pfizer New Haven Clinical Research Unit is conducting a study of a new investigational drug. It is being studied to treat people with inflammatory conditions and diseases. This includes:

    • Ulcerative colitis (inflammation and ulcers in the colon)
    • Alopecia areata (bald patches)
    • Rheumatoid arthritis (RA)
    • Vitiligo (loss of skin pigment)In a previous study, the study drug was given to healthy subjects in single doses of up to 800 mg and multiple doses of up to 400 mg a day for 14 days and the study drug was well tolerated. The dose of study drug in this study will be 200 mg once a day for 11 days. The study drug will be given as four      50 mg tablets which you will swallow. Midazolam and efavirenz will also be given in this study. Midazolam is a marketed sedative. It has a calming or sleep-inducing effect. Efavirenz is a marketed antiretroviral. It works against retroviruses such as Human Immunodeficiency Virus (HIV). You will receive a single oral dose of each of these medications, taken together, twice during the study.

This study involves:

You will be in this study up to about 57 days. This does not include the time between screening and dosing, which can be up to 28 days.

This study involves:

  • 2 dosing periods
  • 17 overnight stays (4 nights for 1 of your admissions; 13 nights for your other admission)
  • 1 follow-up phone call (28 to 35 days after the last dose)There will be at least 10 days between the last dose in 1 period and the first dose in the other period.

Please review the Informed Consent Document: B7981017 revised ICD v03Dec2018

Please review more information about the study: B7981017 Guidelines Restrictions and Dates v06Nov2018